How Big is the RNAi Market | Trends & Opportunities 2026

What is the size of the RNAi Market?

Growth of the RNAi Market is attributed to advances in delivery technologies, rising clinical approvals and late-stage candidates, expanding investment in rare disease and cardiometabolic programs, and improved manufacturing and formulation capabilities.

Key Growth Drivers of the RNAi Market

• Improved delivery platforms enabling extra-hepatic targeting and repeat dosing
• Increasing R&D and late-stage pipelines in oncology, cardiometabolic and rare diseases
• Strategic partnerships and acquisitions accelerating commercialisation and scale-up
• Growing contract development and manufacturing capacity for oligonucleotide drugs
• Regulatory progress and reimbursement discussions for novel RNAi therapeutics

RNAi Market Trends

RNAi Market is seeing wider adoption of GalNAc conjugates for liver delivery and rapid clinical progress for cardiometabolic and rare disease targets, while long-acting dosing regimens are improving patient adherence. Companies are combining RNAi with complementary modalities and focusing on indications with clear biomarker endpoints to speed approvals. Manufacturing scale-up and cost optimisation for oligonucleotide synthesis are making more programs commercially feasible. Cloud-enabled real-world evidence generation and payer engagement strategies are emerging as commercial imperatives.

Emerging Developments in the RNAi Market

Emerging developments include successful launches and rollouts of approved RNAi drugs, progress in extra-hepatic delivery vectors, and next-generation chemistries that extend durability of effect. Multiple late-stage trials in lipid management and rare metabolic diseases are expected to read out over the next few years, creating new commercial pathways. There is growing interest in combination regimens and in leveraging AI for target selection and sequence optimisation. Investment in CDMO capacity and regulatory interactions for oligonucleotide analytics are accelerating adoption across industry.

List of Leading Companies in the RNAi Market

Below is a comprehensive list of the leading market players driving growth in this sector:

1. Alnylam Pharmaceuticals

This company pioneers approved RNAi therapeutics for rare diseases and cardiometabolic indications. It focuses on GalNAc delivery platforms and advancing a broad clinical pipeline.

2. Novartis

This company commercializes inclisiran (lipid-lowering) and partners on RNAi programs. It invests in late-stage clinical development, commercialization, and expanding RNAi therapeutic portfolios.

3. Arrowhead Pharmaceuticals

This company develops targeted RNAi therapies using advanced delivery platforms. It focuses on liver and systemic disease programs, delivering innovative oligonucleotide therapeutics.

4. Silence Therapeutics

This company advances siRNA candidates for cardiovascular and rare disease targets. It develops expertise in oligonucleotide delivery and formulation technologies.

5. Dicerna (Novo Nordisk / Dicerna tech)

This company develops GalXC and RNAi delivery platforms targeting liver diseases and beyond. It collaborates with strategic partners for clinical development and therapeutic innovation.

6. Sirnaomics

This company advances systemic and inhaled RNAi candidates across oncology, fibrosis, and infectious diseases. It leverages proprietary chemistries for improved efficacy and delivery.

7. Aro Biotherapeutics

This company focuses on next-generation RNAi delivery platforms. It targets extra-hepatic tissues and novel therapeutic areas beyond traditional liver-focused RNAi therapies.

8. Ionis Pharmaceuticals

This company specializes in oligonucleotide therapeutics, including antisense and RNA approaches. It provides platform expertise, partnerships, and manufacturing support for innovative therapies.

9. Aligos Therapeutics

This company develops oligonucleotide therapies with novel delivery and formulation strategies. It aims for durable effects and treatment solutions for chronic diseases.

10. Benitec Biopharma / Phio

These companies pursue gene-silencing platforms and delivery innovations for niche indications. They focus on RNAi platform development and licensing opportunities.

How Big is the RNAi Market : FAQs